title: Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells.
abstract: The inability to obtain sufficient numbers of transduced cells remains a limitation in gene therapy. One strategy to address this limitation is in vivo pharmacologic selection of transduced cells. We have previously shown that knockdown of HPRT using lentiviral delivered shRNA facilitates efficient selection of transduced murine hematopoietic progenitor cells (HPC) using 6-thioguanine (6TG). Herein, we now extend these studies to human HPC. We tested multiple shRNA constructs in human derived cell lines and identified the optimal shRNA sequence for knockdown of HPRT and 6TG resistance. We then tested this vector in human umbilical cord blood derived HPC in vitro and in NOD/SCID recipients. Knockdown of HPRT effectively provided resistance to 6TG in vitro. 6TG treatment of mice resulted in increased percentages of transduced human CD45(+) cells in the peripheral blood and in the spleen in particular, in both myeloid and lymphoid compartments. 6TG treatment of secondary recipients resulted in higher percentages of transduced human cells in the bone marrow, confirming selection from the progeny of long-term repopulating HPCs. However, the extent of selection of cells in the bone marrow at the doses of 6TG tested and the toxicity of higher doses, suggest that this strategy may be limited to selection of more committed progenitor cells. Together, these data suggest that human HPC can be programmed to be resistant to purine analogs, but that HPRT knockdown/6TG-based selection may not be robust enough for in vivo selection.
authors.affiliation: Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
authors.forename: Rashmi
authors.initials: R
authors.lastname: Choudhary
authors.forename: Dmitry
authors.initials: D
authors.lastname: Baturin
authors.forename: Susan
authors.initials: S
authors.lastname: Fosmire
authors.forename: Brian
authors.initials: B
authors.lastname: Freed
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Porter
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D002460:Cell Line; D004351:Drug Resistance / Q000187:drug effects / Q000235:genetics; D005260:Female; D055785:Gene Knockdown Techniques; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency* / Q000235:genetics*; D008214:Lymphocytes / Q000166:cytology; D051379:Mice; D022423:Myeloid Cells / Q000166:cytology; D013866:Thioguanine / Q000494:pharmacology; D014161:Transduction, Genetic / Q000379:methods*; D014470:Umbilical Cord / Q000166:cytology
chemical_list: D018952:Antigens, CD34; D007041:Hypoxanthine Phosphoribosyltransferase; D013866:Thioguanine
references.citation: Science. 1992 Jul 3;257(5066):99-103
references.pmid: 1352414
references.citation: Leukemia. 1997 Sep;11(9):1469-77
references.pmid: 9305600
references.citation: N Engl J Med. 2002 Apr 18;346(16):1185-93
references.pmid: 11961146
references.citation: Ann Pharmacother. 2007 Jan;41(1):21-8
references.pmid: 17200426
references.citation: Hum Gene Ther. 2011 Jun;22(6):697-710
references.pmid: 21319998
references.citation: Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):206-10
references.pmid: 8552605
references.citation: Br J Haematol. 2000 Apr;109(1):13-23
references.pmid: 10848777
references.citation: Science. 2009 Nov 6;326(5954):818-23
references.pmid: 19892975
references.citation: Blood. 2008 Dec 1;112(12):4466-74
references.pmid: 18587011
references.citation: Blood. 2000 May 15;95(10):3078-84
references.pmid: 10807772
references.citation: Nat Biotechnol. 2006 Jun;24(6):687-96
references.pmid: 16732270
references.citation: Exp Hematol. 2012 Jan;40(1):3-13.e3
references.pmid: 22001673
references.citation: N Engl J Med. 2009 Jan 29;360(5):447-58
references.pmid: 19179314
references.citation: Nature. 1977 Jun 30;267(5614):841-3
references.pmid: 197411
references.citation: Nat Med. 2006 Apr;12(4):401-9
references.pmid: 16582916
references.citation: J Pharmacol Exp Ther. 2002 Jan;300(1):50-6
references.pmid: 11752096
references.citation: Mol Ther. 2008 Mar;16(3):439-49
references.pmid: 18227842
references.citation: Blood. 2006 Oct 15;108(8):2545-53
references.pmid: 16825499
references.citation: Hum Gene Ther. 1998 Jan 1;9(1):33-42
references.pmid: 9458240
references.citation: Nat Med. 2000 Jun;6(6):652-8
references.pmid: 10835681
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7
references.pmid: 17090675
references.citation: J Exp Med. 1987 Jul 1;166(1):210-8
references.pmid: 3298524
references.citation: J Clin Invest. 2003 Nov;112(10):1561-70
references.pmid: 14617757
references.citation: Blood. 2002 Mar 15;99(6):1909-12
references.pmid: 11877259
references.citation: Science. 2003 Oct 17;302(5644):415-9
references.pmid: 14564000
references.citation: Blood. 1990 Jan 15;75(2):337-43
references.pmid: 1967217
references.citation: J Clin Invest. 2010 Jul;120(7):2345-54
references.pmid: 20551514
references.citation: Sci Transl Med. 2012 May 9;4(133):133ra57
references.pmid: 22572881
references.citation: Clin Cancer Res. 1999 Jul;5(7):1619-28
references.pmid: 10430060
references.citation: N Engl J Med. 2010 Nov 11;363(20):1918-27
references.pmid: 21067383
references.citation: J Clin Oncol. 1998 Jan;16(1):165-72
references.pmid: 9440739